John Wiley & Sons, Inc., today announced the final step of an extended publishing partnership with the Federation of European Biochemical Societies (FEBS) with the move of Molecular Oncology from January 2017 to join the other three FEBS publications published by Wiley; The FEBS Journal, FEBS Letters, and FEBS Open Bioat FEBS Press. FEBS has become one of Europe’s largest organisations in the molecular life sciences, providing a voice to a large part of the academic research and teaching community in Europe.
Molecular Oncology publishes high-impact discoveries and technical advances in basic, clinical and discovery-driven translational cancer research, and has an Impact Factor of 5.367. When Molecular Oncology joins Wiley in January 2017 it will also make the change to become a fully Open Access journal.
This expanded partnership adds this fourth scientific journal to the three other leading journals published by FEBS Press with Wiley.
The FEBS Journal is a leading journal publishing novel, high-quality research in any area of the molecular life sciences. Since its launch in 1967 it has maintained its position as an influential journal in the field, publishing with Wiley since 1999. The FEBS Journal has a 2015 Impact Factor of 4.237.
FEBS Letters is dedicated to the rapid publication of research letters that merit urgent publication. Launched in 1970 and publishing with Wiley from 2016, the journal now has an Impact Factor of 3.519.
FEBS Open Bio is a fully Open Access journal publishing research in molecular and cellular life sciences in both health and disease, with an Impact Factor of 2.101.
With Molecular Oncology’s transition to Wiley, all four journals will be discoverable on the new FEBS Press platform on Wiley Online Library. FEBS Press will ensure the journals continue to serve and support the research community and remain the journals of choice for authors and readers.
Professor László Fésüs from the University of Debrecen in Hungary and Chair of the Publication Committee forFEBS said,“Joining Molecular Oncology to the three other journals completes the process establishing the FEBS Press platform and strengthens our long standing, highly valued collaboration with Wiley.”
“We are delighted to welcome Molecular Oncology as the fourth FEBS Press journal to publish with Wiley, and further extend and cement what is already a close and successful publishing partnership,” said David Nicholson, VP and Publishing Director at Wiley.
About The Federation of European Biochemical Societies
Founded on 1st January 1964, The Federation of European Biochemical Societies (FEBS) has become one of Europe's largest organizations in the molecular life sciences, with over 36,000 members across more than 35 biochemistry and molecular biology societies (its 'Constituent Societies') in different countries of Europe and neighbouring regions. FEBS thereby provides a voice to a large part of the academic research and teaching community in Europe and beyond. As a charitable organization, FEBS promotes, encourages and supports biochemistry, molecular biology, cell biology, molecular biophysics and related research areas in a variety of ways, with an emphasis in many programmes on scientific exchange and cooperation between scientists working in different countries, and on promotion of the training of early-career scientists.
About The FEBS Journal
The FEBS Journal is an international journal devoted to the rapid publication of full-length papers covering a wide range of topics in any area of the molecular life sciences. The criteria for acceptance are originality and high quality research, which will provide novel perspectives in a specific area of research, and will be of interest to our broad readership.
About FEBS Letters
FEBS Letters is a world-renowned journal for rapid publication of short reports describing novel and specific effects with a biologically or biochemically significant function. Bringing together important developments in the molecular biosciences, FEBS Letters provides an international forum for Research Letters, Reviews and Hypotheses describing or discussing mechanistic insights at the molecular level, which would be interesting to a broad readership.
About FEBS Open Bio
FEBS Open Bio is an Open Access journal for the rapid publication of research articles in molecular and cellular life sciences in both health and disease. The journal's peer review process focuses on the technical soundness of papers, leaving the assessment of their impact and importance to the scientific community. Articles are free to all readers and are included in PubMedCentral and indexed in PubMed.
About Molecular Oncology
Molecular Oncology highlights new discoveries, approaches, and technical developments, in basic, clinical and discovery-driven translational cancer research. The journal also provides an international forum for debating cancer issues, and for integrating the input of all stakeholders. Molecular Oncology’s News section includes regular updates on new developments in Cancer Research Infrastructures (biobanks, databases, genomic resources).
Wiley (wiley.com) is a global provider of knowledge and knowledge-enabled services that improve outcomes in areas of research, professional practice and education. Through the Research segment, the Company provides digital and print scientific, technical, medical, and scholarly journals, reference works, books, database services, and advertising. The Professional Development segment provides digital and print books, online assessment and training services, and test prep and certification. In Education, Wiley provides education solutions including online program management services for higher education institutions and course management tools for instructors and students, as well as print and digital content.